Please assess the completion status of the following clinical trial:

Trial Title: Efficiency Evaluation of Photodynamic Therapy With Photofrin® on Unresectable Type III or IV Cholangiocarcinomas

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Obtention of a written informed consent.~* Patient over 18.~* Patient with a type III or IV (according to Bismuth classification) histologically proved cholangiocarcinoma ; histologic diagnosis must be proved by biliary brushing, bile cytology, endobiliary biopsy under scope control with pediatric pliers, or by cytologic puncture under scan or echoendscopic control.~* Patient with Karnofsky score ≥ 50 %~* Patient with an efficient initial biliary drainage with prothesis.~* Cancer classified maximum T3N1M1, but only with intrahepatic metastasis occupying less than 25% of hepatic parenchyme (according to TNM cancer classification of extrahepatic biliary ducts' cancers).~* Patient capable of fill in the quality of life questionnaire.~Exclusion Criteria:~* No written informed consent.~* Type I and II cholangiocarcinoma according to Bismuth classification.~* Patients with ASA score 4.~* Patients with clinical and biological signs of biliary infection.~* Patients with a severe visceral disease other than cholangiocarcinoma.~* Patients without an efficient initial biliary drainage.~* Patients with extrahepatic visceral metastasis, except perihilar ganglionic metastasis classified T4N1M+ according to TNM classification.~* Patients whose cholangiocarcinoma has already been resected.~* Patients under or already treated by radiotherapy or chemotherapy treatment for cholangiocarcinoma.~* Patients first treated with metallic prothesis.~* Patients with a contraindication to MRI.~* Patients with porphyria or hypersensibility to porphyrins.~* Patient treated by a non authorized treatment at the time of inclusion.~* Pregnant, parturient or breastfeeding women.~* Non menopaused woman without an efficient contraception.~* Patient under 18.~* Person over 18 under protection according to French Public Health Code.~* Person not affiliated to a social security regimen, or benefiting from such a regimen.~* Person in a exclusion period of another biomedical study.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): PDT
- 2 (Type: NO_INTERVENTION): None

Based on this trial design, predict the completion outcome and termination type (if applicable).